Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity

Checkpoint blockade immunotherapy is now a first-line treatment option for patients with melanoma. Despite achieving objective responses in about half of patients, the exact immune mechanisms elicited and those required for therapeutic success have not been clearly identified. Insight into these mec...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunol Immunother
Main Authors: Kuehm, Lindsey M., Wolf, Kyle, Zahour, John, DiPaolo, Richard J., Teague, Ryan M.
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2019
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6939620/
https://ncbi.nlm.nih.gov/pubmed/31104075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-019-02346-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items